Department of Cutaneous Oncology, Moffitt Cancer Center, 10920 McKinley Drive Room 4123, Tampa, FL, USA.
Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
Clin Exp Metastasis. 2024 Aug;41(4):457-460. doi: 10.1007/s10585-023-10228-4. Epub 2023 Aug 9.
In-transit metastasis (ITM) develop in approximately 1 in 10 patients with melanoma and the disease course can vary widely. Surgical resection is the gold-standard treatment; however, ITM are often surgically unresectable due to size, distribution, and/or anatomic involvement. Oncolytic viral therapies are one category of non-surgical treatment options available for ITM. They induce tumor cell lysis and systemic anti-tumor activity through selective infection of tumor cells by naturally occurring or genetically modified factors. While there are numerous oncolytic viral therapies in various stages of development for the treatment of ITM, this discussion focuses on the mechanism and available literature for the two most established herpes virus-based therapies.
约 10%的黑色素瘤患者会发生转移（ITM），且疾病进程差异较大。手术切除是金标准治疗方法；然而，由于肿瘤大小、分布和/或解剖部位受累，ITM 通常无法手术切除。溶瘤病毒疗法是 ITM 的非手术治疗选择之一。它们通过天然存在或基因修饰的因子选择性感染肿瘤细胞，诱导肿瘤细胞裂解和全身性抗肿瘤活性。虽然有许多溶瘤病毒疗法处于 ITM 治疗的不同研发阶段，但本文重点讨论两种最成熟的基于单纯疱疹病毒的疗法的作用机制和现有文献。
